x
|
QUARTERLY
REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF
1934
|
¨
|
TRANSITION
REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF
1934
|
Delaware
|
77-0492262
|
|
(State
or other jurisdiction of
incorporation
or organization)
|
(I.R.S.
employer
identification
no.)
|
Large accelerated filer ¨ | Accelerated filer x | Non-accelerated filer ¨ | Smaller reporting company ¨ |
|
Page
|
|||
PART I
|
FINANCIAL
INFORMATION
|
|
||
Item 1.
|
Financial
Statements (unaudited)
|
|
1
|
|
Condensed
Consolidated Balance Sheets
|
|
1
|
||
Condensed
Consolidated Statements of Operations
|
|
2
|
||
Condensed
Consolidated Statements of Cash Flows
|
|
3
|
||
Notes
to Condensed Consolidated Financial Statements
|
|
4
|
||
Item 2.
|
Management’s
Discussion and Analysis of Financial Condition and Results of
Operations
|
|
15
|
|
Item 3.
|
Quantitative
and Qualitative Disclosures About Market Risk
|
|
28
|
|
Item 4.
|
Controls
and Procedures
|
|
29
|
|
PART II
|
OTHER
INFORMATION
|
|
||
Item 1.
|
Legal
Proceedings
|
|
30
|
|
Item 1A
|
Risk
Factors
|
|
30
|
|
Item 2.
|
Unregistered
Sales of Equity Securities and Use of Proceeds
|
|
43
|
|
Item 3.
|
Defaults
Upon Senior Securities
|
|
43
|
|
Item 4.
|
Submission
of Matters to a Vote of Security Holders
|
|
44
|
|
Item 5.
|
Other
Information
|
|
44
|
|
Item 6.
|
Exhibits
|
|
44
|
|
Signature
|
45
|
FINANCIAL
STATEMENTS
|
September
30,
|
December
31,
|
|||||||
2009
|
2008
|
|||||||
Assets
|
||||||||
Current
assets:
|
||||||||
Cash
and cash equivalents
|
$
|
34,302
|
$
|
36,540
|
||||
Marketable
investments
|
62,572
|
60,653
|
||||||
Accounts
receivable, net
|
2,635
|
5,792
|
||||||
Inventories
|
7,884
|
9,927
|
||||||
Deferred
tax asset
|
244
|
4,257
|
||||||
Other
current assets and prepaid expenses
|
2,644
|
1,771
|
||||||
Total
current assets
|
110,281
|
118,940
|
||||||
Property
and equipment, net
|
939
|
1,357
|
||||||
Long-term
investments
|
7,339
|
9,627
|
||||||
Intangibles,
net
|
877
|
1,025
|
||||||
Deferred
tax asset, net of current portion
|
—
|
6,527
|
||||||
Total
assets
|
$
|
119,436
|
$
|
137,476
|
||||
Liabilities
and Stockholders' Equity
|
||||||||
Current
liabilities:
|
||||||||
Accounts
payable
|
$
|
1,212
|
$
|
1,690
|
||||
Accrued
liabilities
|
7,281
|
8,848
|
||||||
Deferred
revenue
|
6,295
|
6,758
|
||||||
Total
current liabilities
|
14,788
|
17,296
|
||||||
Deferred
rent
|
1,548
|
1,713
|
||||||
Deferred
revenue, net of current portion
|
2,331
|
4,907
|
||||||
Income
tax liability
|
882
|
1,452
|
||||||
Total
liabilities
|
19,549
|
25,368
|
||||||
Commitments
and Contingencies (Note 8)
|
||||||||
Stockholders’
equity:
|
||||||||
Common
stock
|
13
|
13
|
||||||
Additional
paid-in capital
|
84,148
|
80,318
|
||||||
Retained
earnings
|
17,247
|
31,410
|
||||||
Accumulated
other comprehensive income (loss)
|
(1,521
|
)
|
367
|
|||||
Total
stockholders’ equity
|
99,887
|
112,108
|
||||||
Total
liabilities and stockholders’ equity
|
$
|
119,436
|
$
|
137,476
|
Three
Months Ended
|
Nine
Months Ended
|
|||||||||||||||
September
30,
|
September
30,
|
|||||||||||||||
2009
|
2008
|
2009
|
2008
|
|||||||||||||
Net
revenue
|
$
|
12,171
|
$
|
19,110
|
$
|
38,266
|
$
|
65,482
|
||||||||
Cost
of revenue
|
4,910
|
7,823
|
15,976
|
25,313
|
||||||||||||
Gross
profit
|
7,261
|
11,287
|
22,290
|
40,169
|
||||||||||||
Operating
expenses:
|
||||||||||||||||
Sales
and marketing
|
5,112
|
8,076
|
18,186
|
28,786
|
||||||||||||
Research
and development
|
1,684
|
1,828
|
4,922
|
5,617
|
||||||||||||
General
and administrative
|
2,121
|
2,583
|
8,257
|
8,547
|
||||||||||||
Litigation
settlement
|
—
|
—
|
850
|
—
|
||||||||||||
Total
operating expenses
|
8,917
|
12,487
|
32,215
|
42,950
|
||||||||||||
Loss
from operations
|
(1,656
|
)
|
(1,200
|
)
|
(9,925
|
)
|
(2,781
|
)
|
||||||||
Interest
and other income, net
|
288
|
733
|
1,398
|
2,491
|
||||||||||||
Other-than-temporary
impairment of long-term investments
|
—
|
(2,372
|
)
|
—
|
(2,372
|
)
|
||||||||||
Loss
before income taxes
|
(1,368
|
)
|
(2,839
|
)
|
(8,527
|
)
|
(2,662
|
)
|
||||||||
Provision
(benefit) for income taxes
|
12,126
|
(86
|
)
|
9,159
|
(28
|
)
|
||||||||||
Net
loss
|
$
|
(13,494
|
)
|
$
|
(2,753
|
)
|
$
|
(17,686
|
)
|
$
|
(2,634
|
)
|
||||
Net
loss per share:
|
||||||||||||||||
Basic
and Diluted
|
$
|
(1.01
|
)
|
$
|
(0.22
|
)
|
$
|
(1.33
|
)
|
$
|
(0.21
|
)
|
||||
Weighted-average
number of shares used in per share calculations:
|
||||||||||||||||
Basic
and Diluted
|
13,382
|
12,780
|
13,274
|
12,762
|
Nine
Months Ended
|
||||||||
September
30,
|
||||||||
2009
|
2008
|
|||||||
Cash
flows from operating activities:
|
||||||||
Net
loss
|
$
|
(17,686
|
)
|
$
|
(2,634
|
)
|
||
Adjustments
to reconcile net loss to net cash provided by (used in) operating
activities:
|
||||||||
Stock-based
compensation
|
3,396
|
3,983
|
||||||
Tax
benefit (deficit) from stock-based compensation
|
(2
|
)
|
49
|
|||||
Depreciation
and amortization
|
664
|
671
|
||||||
Provision
for excess and obsolete inventories
|
247
|
(61
|
)
|
|||||
Other-than-temporary
impairment of long term investments
|
—
|
2,372
|
||||||
Change
in allowance for doubtful accounts
|
550
|
149
|
||||||
Change
in deferred tax asset and deferred tax liability
|
10,540
|
140
|
||||||
Changes
in assets and liabilities:
|
||||||||
Accounts
receivable
|
2,607
|
4,057
|
||||||
Inventories
|
1,796
|
(1,159
|
)
|
|||||
Other
current assets and prepaid expenses
|
572
|
221
|
||||||
Accounts
payable
|
(478
|
)
|
(230
|
)
|
||||
Accrued
liabilities
|
(1,686
|
)
|
(3,557
|
)
|
||||
Deferred
rent
|
(46
|
)
|
56
|
|||||
Deferred
revenue
|
(3,039
|
)
|
1,606
|
|||||
Income
tax liability
|
(570
|
)
|
207
|
|||||
Net
cash provided by (used in) operating activities
|
(3,135
|
)
|
5,870
|
|||||
Cash
flows from investing activities:
|
||||||||
Acquisition
of property and equipment
|
(98
|
)
|
(538
|
)
|
||||
Proceeds
from sales of marketable investments
|
20,794
|
49,969
|
||||||
Proceeds
from maturities of marketable investments
|
10,560
|
18,150
|
||||||
Purchase
of marketable investments
|
(30,795
|
)
|
(58,085
|
)
|
||||
Net
cash provided by investing activities
|
461
|
9,496
|
||||||
Cash
flows from financing activities:
|
||||||||
Proceeds
from exercise of stock options and employee stock purchase
plan
|
436
|
263
|
||||||
Net
cash provided by financing activities
|
436
|
263
|
||||||
Net
increase (decrease) in cash and cash equivalents
|
(2,238
|
)
|
15,629
|
|||||
Cash
and cash equivalents at beginning of period
|
36,540
|
11,054
|
||||||
Cash
and cash equivalents at end of period
|
$
|
34,302
|
$
|
26,683
|
September
30, 2009
|
Amortized
Cost
|
Gross
Unrealized
Gains
|
Gross
Unrealized
Losses
|
Fair
Market
Value
|
|||||||||
Cash
and cash equivalents
|
$
|
34,302
|
$
|
—
|
$
|
—
|
$
|
34,302
|
|||||
Marketable
investments:
|
|||||||||||||
Municipal
securities
|
62,127
|
301
|
(11)
|
62,417
|
|||||||||
Auction
rate securities
|
126
|
29
|
—
|
155
|
|||||||||
Total
marketable investments
|
62,253
|
330
|
(11)
|
62,572
|
|||||||||
Long-term
investments in auction rate securities
|
8,920
|
—
|
(1,581)
|
7,339
|
|||||||||
$
|
105,475
|
$
|
330
|
$
|
(1,592)
|
$
|
104,213
|
December 31,
2008
|
Amortized
Cost
|
Gross
Unrealized
Gains
|
Gross
Unrealized
Losses
|
Fair
Market
Value
|
|||||||||
Cash
and cash equivalents
|
$
|
36,540
|
$
|
—
|
$
|
—
|
$
|
36,540
|
|||||
Marketable
investments:
|
|||||||||||||
Municipal
securities
|
59,837
|
566
|
—
|
60,403
|
|||||||||
Auction
rate securities
|
219
|
31
|
—
|
250
|
|||||||||
Total
marketable investments
|
60,056
|
597
|
—
|
60,653
|
|||||||||
Long-term
investments in auction rate securities
|
9,627
|
—
|
—
|
9,627
|
|||||||||
$
|
106,223
|
$
|
597
|
$
|
—
|
$
|
106,820
|
·
|
Level
1: Quoted prices (unadjusted) in active markets that are accessible at the
measurement date for assets or
liabilities.
|
·
|
Level
2: Directly or indirectly observable inputs as of the reporting date
through correlation with market data, including quoted prices for similar
assets and liabilities in active markets and quoted prices in markets that
are not active. Level 2 also includes assets and liabilities that are
valued using models or other pricing methodologies that do not require
significant judgment since the input assumptions used in the models, such
as interest rates and volatility factors, are corroborated by readily
observable data from actively quoted markets for substantially the full
term of the financial instrument.
|
·
|
Level
3: Unobservable inputs that are supported by little or no market activity
and reflect the use of significant management judgment. These values are
generally determined using pricing models for which the assumptions
utilize management’s estimates of market participant
assumptions.
|
Level
1
|
Level
2
|
Level
3
|
Total
|
|||||||||||||
Cash
equivalents
|
$
|
31,868
|
$
|
—
|
$
|
—
|
$
|
31,868
|
||||||||
Marketable
investments:
|
||||||||||||||||
Available-for-sale
securities
|
—
|
62,572
|
—
|
62,572
|
||||||||||||
Long-term
investments:
|
||||||||||||||||
Available-for-sale
ARS
|
—
|
—
|
7,339
|
7,339
|
||||||||||||
Total
assets at fair value
|
$
|
31,868
|
$
|
62,572
|
$
|
7,339
|
$
|
101,779
|
Three Months
Ended
September 30,
2009
|
Nine Months
Ended
September 30,
2009
|
|||||||
Beginning
Balance
|
$ | 7,640 | $ | 9,627 | ||||
Transfers
out of Level 3
|
(296 | ) | (2,326 | ) | ||||
Unrealized
gain (loss) included in other comprehensive income
|
(5 | ) | 38 | |||||
Ending
Balance
|
$ | 7,339 | $ | 7,339 |
September
30,
2009
|
December 31,
2008
|
|||||||
Tax
receivable
|
$
|
1,437
|
$
|
235
|
||||
Deposits
|
542
|
824
|
||||||
Prepaid
expense
|
665
|
712
|
||||||
$
|
2,644
|
$
|
1,771
|
September
30,
2009
|
December 31,
2008
|
|||||||
Raw
materials
|
$ | 4,643 | $ | 5,071 | ||||
Finished
goods
|
3,241 | 4,856 | ||||||
$ | 7,884 | $ | 9,927 |
September
30, 2009
|
|||||||||
Gross Carrying
Amount
|
Accumulated
Amortization
Amount
|
Net Carrying
Amount
|
|||||||
Patent
sublicense
|
$ | 1,218 | $ | 483 | $ | 735 | |||
Technology
patent sublicense
|
538 | 396 | 142 | ||||||
Other
intangibles
|
20 | 20 | — | ||||||
Total
|
$ | 1,776 | $ | 899 | $ | 877 |
December 31,
2008
|
|||||||||
Gross Carrying
Amount
|
Accumulated
Amortization
Amount
|
Net Carrying
Amount
|
|||||||
Patent
sublicense
|
$ | 1,218 | $ | 379 | $ | 839 | |||
Technology
sublicense
|
538 | 356 | 182 | ||||||
Other
intangibles
|
20 | 16 | 4 | ||||||
Total
|
$ | 1,776 | $ | 751 | $ | 1,025 |
Fiscal
Year Ending December 31,
|
||||
2009
remainder
|
$
|
47
|
||
2010
|
192
|
|||
2011
|
192
|
|||
2012
|
158
|
|||
2013
|
138
|
|||
Thereafter
|
150
|
|||
Total
|
$
|
877
|
Three Months Ended
September 30,
|
Nine Months
Ended
September 30,
|
|||||||||||||||
2009
|
2008
|
2009
|
2008
|
|||||||||||||
Cost
of sales
|
$
|
161
|
$
|
222
|
$
|
568
|
$
|
648
|
||||||||
Sales
and marketing
|
250
|
440
|
817
|
1,290
|
||||||||||||
Research
and development
|
116
|
170
|
364
|
443
|
||||||||||||
General
and administrative
|
368
|
494
|
1,647
|
1,602
|
||||||||||||
Total
stock-based compensation expense
|
$
|
895
|
$
|
1,326
|
$
|
3,396
|
$
|
3,983
|
Three Months Ended
September 30,
|
Nine Months
Ended
September 30,
|
|||||||||||||||
2009
|
2008
|
2009
|
2008
|
|||||||||||||
Numerator:
|
||||||||||||||||
Net
loss available to common stockholders – Basic and Diluted
|
$
|
(13,494
|
)
|
$
|
(2,753
|
)
|
$
|
(17,686
|
)
|
$
|
(2,634
|
)
|
||||
Denominator:
|
||||||||||||||||
Weighted-average
number of common shares outstanding used in computing basic and diluted
net loss per share
|
13,382
|
12,780
|
13,274
|
12,762
|
Three
Months Ended
September
30,
|
Nine
Months Ended
September
30,
|
|||||||||||||||
2009
|
2008
|
2009
|
2008
|
|||||||||||||
Options
to purchase common stock
|
2,846
|
3,160
|
2,769
|
2,812
|
||||||||||||
Restricted
stock units
|
—
|
13
|
7
|
21
|
||||||||||||
Employee
stock purchase plan shares
|
29
|
31
|
63
|
63
|
||||||||||||
Total
|
2,875
|
3,204
|
2,839
|
2,896
|
|
September
30,
|
|||||||
|
2009
|
2008
|
||||||
Beginning
Balance
|
|
$
|
11,665
|
$
|
10,564
|
|||
Add:
Payments received
|
|
4,643
|
7,987
|
|||||
Less:
Revenue recognized
|
|
(7,682
|
)
|
(6,381
|
)
|
|||
Ending
Balance
|
|
$
|
8,626
|
$
|
12,170
|
Three Months Ended
September 30,
|
Nine Months Ended
September 30,
|
||||||||||||||
2009
|
2008
|
2009
|
2008
|
||||||||||||
Net
loss
|
$ |
(13,494
|
)
|
$
|
(2,753
|
)
|
$
|
(17,686
|
)
|
$
|
(2,634
|
)
|
|||
Net
change in unrealized gain (loss) on available-for
sale-securities
|
(105 | ) | 1,733 | 1,635 | (256 | ) | |||||||||
Change in income tax effect on unrealized gain (loss) on available-for sale-securities | (66 | ) | - | 1 | - | ||||||||||
Comprehensive
loss
|
$ | (13,665 | ) | $ | (1,020 | ) | $ | (16,050 | ) | $ | (2,890 | ) |
|
September
30,
|
|||||||
|
2009
|
2008
|
||||||
Balance
at December 31, 2008 and 2007
|
|
$
|
1,916
|
$
|
2,725
|
|||
Add:
Accruals for warranties issued during the period
|
|
1,402
|
3,735
|
|||||
Less:
Settlements made during the period
|
|
(2,229
|
)
|
(4,263
|
)
|
|||
Balance
at September 30, 2009 and 2008
|
|
$
|
1,089
|
$
|
2,197
|
Fiscal
Year Ending December 31,
|
||||
2009
(remainder)
|
$
|
413
|
||
2010
|
1,443
|
|||
2011
|
1,326
|
|||
2012
|
1,431
|
|||
2013
|
1,545
|
|||
Future
minimum rental payments
|
$
|
6,158
|
MANAGEMENT’S
DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF
OPERATIONS
|
·
|
Executive Summary. This
section provides a general description and history of our business, a
brief discussion of our product lines and the opportunities, trends,
challenges and risks we focus on in the operation of our
business.
|
·
|
Critical Accounting Policies
and Estimates. This section describes the key accounting policies
that are affected by critical accounting
estimates.
|
·
|
Recent Accounting
Guidance. This section describes the issuance and effect of new
accounting pronouncements that are and may be applicable to
us.
|
·
|
Results of Operations.
This section provides our analysis and outlook for the significant line
items on our Consolidated Statements of
Operations.
|
·
|
Liquidity and Capital
Resources. This section provides an analysis of our liquidity and
cash flows, as well as a discussion of our commitments that existed as of
September 30, 2009.
|
·
|
Investments
made in our global sales and marketing
infrastructure.
|
·
|
Use
of clinical results to support new aesthetic products and
applications.
|
·
|
Enhanced
luminary development and reference selling efforts (to develop a location
where our products can be displayed and used to assist in selling
efforts).
|
·
|
Customer
demand for our products and consumer demand for the applications they
offer.
|
·
|
Marketing
to physicians in the core dermatology and plastic surgeon specialties, as
well as outside those specialties.
|
·
|
Generating
Service, Upgrade and Titan hand piece refill revenue from our growing
installed base of customers.
|
Three Months Ended
September 30,
|
Nine Months Ended
September 30,
|
|||||||||||||||
2009
|
2008
|
2009
|
2008
|
|||||||||||||
Operating
Ratio:
|
||||||||||||||||
Net
revenue
|
100%
|
100%
|
100%
|
100%
|
||||||||||||
Cost
of revenue
|
40%
|
41%
|
42%
|
39%
|
||||||||||||
Gross
profit
|
60%
|
59%
|
58%
|
61%
|
||||||||||||
Operating
expenses:
|
||||||||||||||||
Sales
and marketing
|
42%
|
42%
|
47%
|
44%
|
||||||||||||
Research
and development
|
14%
|
10%
|
13%
|
9%
|
||||||||||||
General
and administrative
|
17%
|
13%
|
22%
|
13%
|
||||||||||||
Litigation
settlement
|
—%
|
—%
|
2%
|
—%
|
||||||||||||
Total
operating expenses
|
73%
|
65%
|
84%
|
66%
|
||||||||||||
Loss
from operations
|
(13%
|
)
|
(6%
|
)
|
(26%
|
)
|
(5%
|
)
|
||||||||
Interest
and other income, net
|
2%
|
3%
|
4%
|
4%
|
||||||||||||
Other-than-temporary
impairment on long term investments
|
—%
|
(12%
|
)
|
—%
|
(3%
|
)
|
||||||||||
Loss
before income taxes
|
(11%
|
)
|
(15%
|
)
|
(22%
|
)
|
(4%
|
)
|
||||||||
Provision
(benefit) for income taxes
|
100%
|
(1%
|
)
|
24%
|
0%
|
|||||||||||
Net
loss
|
(111%
|
)
|
(14%
|
)
|
(46%
|
)
|
(4%
|
)
|
|
Three Months Ended
September 30,
|
Nine Months Ended
September 30,
|
||||||||||||||||||
(Dollars
in thousands)
|
|
2009
|
% Change
|
2008
|
2009
|
% Change
|
2008
|
|||||||||||||
Revenue
mix by geography:
|
|
|||||||||||||||||||
United
States
|
|
$
|
4,825
|
(49%
|
)
|
$
|
9,498
|
$
|
15,721
|
(54%
|
)
|
$
|
34,266
|
|||||||
International
|
|
7,346
|
(24%
|
)
|
9,612
|
22,545
|
(28%
|
)
|
31,216
|
|||||||||||
Consolidated
total revenue
|
|
$
|
12,171
|
(36%
|
)
|
$
|
19,110
|
$
|
38,266
|
(42%
|
)
|
$
|
65,482
|
|||||||
|
||||||||||||||||||||
United
States as a percentage of total revenue
|
|
40%
|
50%
|
41%
|
52%
|
|||||||||||||||
International
as a percentage of total revenue
|
|
60%
|
50%
|
59%
|
48%
|
|||||||||||||||
Revenue
mix by product category:
|
|
|||||||||||||||||||
Products
|
|
$
|
6,322
|
(51%
|
)
|
$
|
12,920
|
$
|
20,024
|
(57%
|
)
|
$
|
46,610
|
|||||||
Upgrades
|
|
1,352
|
(31%
|
)
|
1,948
|
4,307
|
(32%
|
)
|
6,333
|
|||||||||||
Service
|
|
3,210
|
10%
|
2,920
|
9,860
|
19%
|
8,311
|
|||||||||||||
Titan
hand piece refills
|
|
1,287
|
(3%
|
)
|
1,322
|
4,075
|
(4%
|
)
|
4,228
|
|||||||||||
Consolidated
total revenue
|
|
$
|
12,171
|
(36%
|
)
|
$
|
19,110
|
$
|
38,266
|
(42%
|
)
|
$
|
65,482
|
|
Three Months Ended
September 30,
|
Nine
Months Ended September 30,
|
||||||||||||||||||
(Dollars
in thousands)
|
|
2009
|
% Change
|
2008
|
2009
|
% Change
|
2008
|
|||||||||||||
Gross
profit
|
|
$
|
7,261
|
(36%
|
)
|
$
|
11,287
|
$
|
22,290
|
(45%
|
)
|
$
|
40,169
|
|||||||
As
a percentage of total revenue
|
|
60%
|
59%
|
58%
|
61%
|
(i)
|
Lower
overall revenue, due to lower volume, which resulted in reduced leverage
of our manufacturing and service department
expenses;
|
(ii)
|
Higher
Service and Titan refill revenue, as a percentage of our total revenue,
which has a lower gross margin than our total revenue;
and
|
(iii)
|
Higher
international distributor revenue, as a percentage of total revenue, which
has a lower gross margin than our direct business; partially offset
by
|
(iv)
|
Reduced
manufacturing expenses resulting primarily from headcount reductions and
improved product reliability.
|
|
Three Months Ended
September 30,
|
Nine
Months Ended September 30,
|
||||||||||||||||||
(Dollars
in thousands)
|
|
2009
|
% Change
|
2008
|
2009
|
% Change
|
2008
|
|||||||||||||
Sales
and marketing
|
|
$
|
5,112
|
(37%
|
)
|
$
|
8,076
|
$
|
18,186
|
(37%
|
)
|
$
|
28,786
|
|||||||
As
a percentage of total revenue
|
|
42%
|
42%
|
47%
|
44%
|
(i)
|
A
decrease in personnel expenses of $1.5 million for the three months and
$5.7 million for the nine months ended September 30, 2009, compared to the
same periods in 2008, due primarily to lower headcount and reduced sales
commission expenses resulting from lower
revenue;
|
(ii)
|
A
decrease in marketing expenses associated with workshop, advertising and
other promotional activities of $258,000 for the three months and $1.9
million for the nine months ended September 30, 2009, compared to the same
periods in 2008; and
|
(iii)
|
A
decrease in travel and related expense of $449,000 for the three months
and $1.6 million for the nine months ended September 30, 2009, compared to
the same periods in 2008, due primarily to lower
headcount.
|
|
Three Months Ended
September 30,
|
Nine
Months Ended September 30,
|
||||||||||||||||||
(Dollars
in thousands)
|
|
2009
|
% Change
|
2008
|
2009
|
% Change
|
2008
|
|||||||||||||
Research
and development
|
|
$
|
1,684
|
(8%
|
)
|
$
|
1,828
|
$
|
4,922
|
(12%
|
)
|
$
|
5,617
|
|||||||
As
a percentage of total revenue
|
|
14%
|
10%
|
13%
|
9%
|
|
Three Months Ended
September 30,
|
Nine
Months Ended September 30,
|
||||||||||||||||||
(Dollars
in thousands)
|
|
2009
|
% Change
|
2008
|
2009
|
% Change
|
2008
|
|||||||||||||
General
and Administrative
|
|
$
|
2,121
|
(18%
|
)
|
$
|
2,583
|
$
|
8,257
|
(3%
|
)
|
$
|
8,547
|
|||||||
As
a percentage of total revenue
|
|
17%
|
13%
|
22%
|
13%
|
(i)
|
A
decrease in personnel expenses of $174,000, primarily attributable to
lower headcount in the United
States;
|
(ii)
|
A
decrease in legal, audit and tax consulting fees of $121,000, due to
reduced fees from the consulting firms, partially offset by higher
consulting fees related to our 2009 Option Exchange
Program;
|
(iii)
|
A
decrease in bad debt expense by $91,000, a decrease in travel and related
expenses of $38,000, and a decrease in facility and equipment expenses of
$38,000.
|
(i)
|
A
decrease in legal, audit and tax consulting fees of $354,000, due to
reduced fees from the consulting firms, partially offset by higher
consulting fees related to our 2009 Option Exchange Program;
and
|
(ii)
|
A
decrease in product litigation settlement expense of $78,000, a decrease
in facility and equipment expenses of $73,000, and a decrease in travel
and related expenses of $66,000, partly offset
by;
|
(iii)
|
An
increase in bad debt expense of $363,000, resulting primarily from one
leasing company that defaulted on its payment in the second quarter of
2009 due to it having significant financial
problems.
|
|
Three Months Ended
September 30,
|
Nine
Months Ended September 30,
|
||||||||||||||||||||||
(Dollars
in thousands)
|
|
2009
|
%
Change
|
2008
|
2009
|
%
Change
|
2008
|
|||||||||||||||||
Interest
income
|
$
|
288
|
(61%
|
) |
$
|
741
|
$
|
1,148
|
(54% | ) |
$
|
2,485
|
||||||||||||
Other
income (expense), net
|
—
|
N/A |
(8
|
)
|
250
|
N/A |
6
|
|||||||||||||||||
Total
Interest and other income, net
|
|
$
|
288
|
(61%
|
)
|
$
|
733
|
$
|
1,398
|
(44%
|
)
|
$
|
2,491
|
(i)
|
A
decrease in interest income of $453,000 for the three months and $1.3
million for the nine months ended September 30, 2009, compared to the same
periods in 2008, due primarily to reduced tax-exempt interest yields as a
result of the Federal Reserve cutting interest rates; which was partially
offset by
|
(ii)
|
An
increase in net foreign exchange gains of $223,000 for the nine months
ended September 30, 2009, compared to the same period in 2008, due
primarily to translation gains resulting form the devaluation of the US
dollar relative to the currencies of our foreign
subsidiaries.
|
|
Three Months Ended
September 30,
|
Nine
Months Ended September 30,
|
||||||||||||||||||||||
(Dollars
in thousands)
|
|
2009
|
Change
|
2008
|
2009
|
Change
|
2008
|
|||||||||||||||||
Loss
before income taxes
|
|
$
|
(1,368
|
)
|
$
|
1,471
|
$
|
(2,839
|
)
|
$
|
(8,527
|
)
|
$
|
(5,865
|
)
|
$
|
(2,662
|
)
|
||||||
Provision
(benefit) for income taxes
|
|
12,126
|
12,212
|
(86
|
)
|
9,159
|
9,187
|
(28
|
)
|
|||||||||||||||
Effective
tax rate
|
N/A
|
3%
|
N/A
|
1%
|
September
30, 2009
|
December 31, 2008
|
Change
|
||||||||||
Cash
and cash equivalents
|
$
|
34,302
|
$
|
36,540
|
$
|
(2,238
|
)
|
|||||
Marketable
investments
|
62,572
|
60,653
|
1,919
|
|||||||||
Long-term
investments
|
7,339
|
9,627
|
(2,288
|
)
|
||||||||
Total
|
$
|
104,213
|
$
|
106,820
|
$
|
(2,607
|
)
|
|
Nine Months Ended September
30,
|
|||||||
(Dollars
in thousands)
|
|
2009
|
2008
|
|||||
Net
cash flow provided by (used in):
|
|
|||||||
Operating
activities
|
|
$
|
(3,135
|
)
|
$
|
5,870
|
||
Investing
activities
|
|
461
|
9,496
|
|||||
Financing
activities
|
|
436
|
263
|
|||||
Net
increase (decrease) in cash and cash equivalents
|
|
$
|
(2,238
|
)
|
$
|
15,629
|
·
|
$2.3
million used by the net loss of $17.7 million after adjusting for non-cash
related items of $15.4 million- consisting primarily of valuation
allowance on our deferred tax asset of $12.3 million as of December 31,
2008, stock-based compensation expense of $3.4 million, net increase in
the allowance for doubtful accounts of $550,000 due primarily to one
leasing company that has defaulted on its payment and an increase in the
provision for excess and obsolete inventories of $247,000 resulting from
the reduced future demand for our
products;
|
·
|
$3.0
million used as a result of a decrease in deferred revenue due primarily
to a decrease in unit sales volume of Products and Upgrades that included
purchases of extended service contracts, a reduction in our service
contract pricing beginning in 2009, a shift by customers towards
purchasing shorter term contracts, and fewer customers purchasing extended
service contracts in response to improved product reliability and to a
tougher economy; and
|
·
|
$1.7
million used to pay down the higher 2008 year-end accrued liabilities
relating primarily to: (i) lower accrued personnel expenses of
$679,000 due primarily to reduced accruals for commissions and employee
benefit expenses; (ii) reduction of accrued warranty expenses of
$827,000 due primarily to fewer units remaining under warranty;
(iii) reduction of the income taxes payable balance by $285,000; and
(iv) net reduction of $245,000 of accrued royalties due to the
reduced revenue in the third quarter of 2009. This was partially offset by
higher accrued legal settlement expense of $850,000 relating to our TCPA
litigation matter (see “Litigation” in Note 8 of Notes to the Condensed
Consolidated Financial Statements in Part I, Item 1 of this quarterly
report of Form 10-Q); partially offset
by
|
·
|
$2.6
million of cash generated by the decrease in gross accounts receivable
balance from December 31, 2008 to September 30, 2009 that resulted from
the collection of the higher 2008 year-end accounts receivable balances;
and
|
·
|
$1.8
million generated by the decrease in gross inventory balance from December
31, 2009 to September 30, 2009, that resulted from slowing our inventory
build to better match the reduced sales of our
products.
|
·
|
$4.7
million generated from net loss of $2.6 million after adjusting for
non-cash related items primarily consisting of $4.0 million of stock-based
compensation, other-than-temporary impairment of long term investments of
$2.4 million, and depreciation and amortization of
$671,000;
|
·
|
$4.1
million of cash generated from the collection of the higher accounts
receivable balance as of December 31,
2007;
|
·
|
$1.6
million of cash generated due to an increase in deferred revenue resulting
primarily from higher service contract revenue; partially offset
by
|
·
|
$3.6
million used to pay down the higher year-end accrued liabilities relating
primarily to personnel expenses of $410,000, net reduction of $1.1 million
of the income tax payable due to the payment of the 2007 year-end income
tax liability, net reduction of $1.0 million of royalty accrual, and
$528,000 relating to the reduction in accrued warranty costs due primarily
to fewer units remaining under warranty;
and
|
·
|
$1.2
million cash used as a result of the increase in inventories due to the
lower than expected revenue in the first nine months of 2008 and to ramp
up production for our Pearl Fractional product that started shipping in
September 2008.
|
·
|
$31.4
million in net proceeds from the sale and maturity of marketable
investments and long-term investments; partially offset
by
|
·
|
$30.8
million of cash used to purchase marketable
investments.
|
·
|
$68.1
million in net proceeds from the sale and maturity of marketable
investments and long-term investments; partially offset
by
|
·
|
$58.1
million of cash used to purchase marketable investments;
and
|
·
|
$538,000
cash used to purchase property and equipment primarily for the research
and development function.
|
QUANTITATIVE
AND QUALITATIVE DISCLOSURES ABOUT MARKET
RISK
|
CONTROLS
AND PROCEDURES
|
LEGAL
PROCEEDINGS
|
RISK
FACTORS
|
·
|
Current
lack of credit financing for some of our potential
customers;
|
·
|
Poor
financial performance of market segments that try introducing aesthetic
procedures to their businesses;
|
·
|
The
inability to differentiate our products from those of our
competitors;
|
·
|
Reduced
patient demand for elective aesthetic
procedures;
|
·
|
Failure
to build and maintain relationships with opinion leaders within the
various market segments;
|
·
|
An
increase in malpractice lawsuits;
and
|
·
|
Our
ability to develop and market our products to the core market specialties
of dermatologists and plastic
surgeons.
|
·
|
Difficulties
in staffing and managing our foreign
operations;
|
·
|
Export
restrictions, trade regulations and foreign tax
laws;
|
·
|
Fluctuating
foreign currency exchange rates;
|
·
|
Foreign
certification and regulatory
requirements;
|
·
|
Lengthy
payment cycles and difficulty in collecting accounts
receivable;
|
·
|
Customs
clearance and shipping delays;
|
·
|
Political
and economic instability;
|
·
|
Lack
of awareness of our brand in international
markets;
|
·
|
Preference
for locally-produced products; and
|
·
|
Reduced
protection for intellectual property rights in some
countries.
|
·
|
Success
and timing of new product development and
introductions;
|
·
|
Product
performance;
|
·
|
Product
pricing;
|
·
|
Quality
of customer support;
|
·
|
Development
of successful distribution channels, both domestically and
internationally; and
|
·
|
Intellectual
property protection.
|
·
|
Develop
and acquire new products that either add to or significantly improve our
current products;
|
·
|
Convince
our customers and prospects that our new products or upgrades would be an
attractive revenue-generating addition to their
practices;
|
·
|
Sell
our products to a broad customer
base;
|
·
|
Identify
new markets and alternative applications for our
technology;
|
·
|
Protect
our existing and future products with defensible intellectual property;
and
|
·
|
Satisfy
and maintain all regulatory requirements for
commercialization.
|
·
|
Consumer
disposable income and access to consumer credit, which as a result of the
unstable economy, may have been significantly
impacted;
|
·
|
The
cost of procedures performed using our
products;
|
·
|
The
cost, safety and effectiveness of alternative treatments, including
treatments which are not based upon laser or other energy-based
technologies and treatments which use pharmaceutical
products;
|
·
|
The
success of our sales and marketing efforts;
and
|
·
|
The
education of our customers and patients on the benefits and uses of our
products, compared to competitors’ products and
technologies.
|
·
|
The
general market conditions unrelated to our operating
performance;
|
·
|
Sales
of large blocks of our common stock, including sales by our executive
officers, directors and our large institutional
investors;
|
·
|
Quarterly
variations in our, or our competitors’ results of
operations;
|
·
|
Changes
in analysts’ estimates, investors’ perceptions, recommendations by
securities analysts or our failure to achieve analysts’
estimates;
|
·
|
The
announcement of new products or service enhancements by us or our
competitors;
|
·
|
The
announcement of the departure of a key employee or executive
officer;
|
·
|
Regulatory
developments or delays concerning our, or our competitors’ products;
and
|
·
|
The
initiation of litigation by us or against
us.
|
·
|
Warning
letters, fines, injunctions, consent decrees and civil
penalties;
|
·
|
Repair,
replacement, recall or seizure of our
products;
|
·
|
Operating
restrictions or partial suspension or total shutdown of
production;
|
·
|
Refusing
our requests for 510(k) clearance or pre-market approval of new products,
new intended uses, or modifications to existing
products;
|
·
|
Withdrawing
510(k) clearance or pre-market approvals that have already been granted;
and
|
·
|
Criminal
prosecution.
|
·
|
Interruption
of supply resulting from modifications to or discontinuation of a
supplier’s operations;
|
·
|
Delays
in product shipments resulting from uncorrected defects, reliability
issues or a supplier’s variation in a
component;
|
·
|
A
lack of long term supply arrangements for key components with our
suppliers;
|
·
|
Inability
to obtain adequate supply in a timely manner, or on reasonable
terms;
|
·
|
Difficulty
locating and qualifying alternative suppliers for our components in a
timely manner;
|
·
|
Production
delays related to the evaluation and testing of products from alternative
suppliers and corresponding regulatory qualifications;
and
|
·
|
Delay
in supplier deliveries.
|
·
|
Loss
of customer orders and delay in order
fulfillment;
|
·
|
Damage
to our brand reputation;
|
·
|
Increased
cost of our warranty program due to product repair or
replacement;
|
·
|
Inability
to attract new customers;
|
·
|
Diversion
of resources from our manufacturing and research and development
departments into our service department;
and
|
·
|
Legal
action.
|
·
|
A
classified board of directors;
|
·
|
Advance
notice requirements to stockholders for matters to be brought at
stockholder meetings;
|
·
|
A
supermajority stockholder vote requirement for amending certain provisions
of our Amended and Restated Certificate of Incorporation and
bylaws;
|
·
|
Limitations
on stockholder actions by written consent;
and
|
·
|
The
right to issue preferred stock without stockholder approval, which could
be used to dilute the stock ownership of a potential hostile
acquirer.
|
UNREGISTERED
SALES OF EQUITY SECURITIES AND USE OF
PROCEEDS
|
DEFAULTS
UPON SENIOR SECURITIES
|
SUBMISSION
OF MATTERS TO A VOTE OF SECURITY
HOLDERS
|
OTHER
INFORMATION
|
ITEM 6.
|
EXHIBITS
|
Exhibit No.
|
Description
|
|
3.2(1)
|
Amended
and Restated Certificate of Incorporation of the Registrant
(Delaware).
|
|
3.4(1)
|
Bylaws
of the Registrant.
|
|
4.1(2)
|
Specimen
Common Stock certificate of the Registrant.
|
|
10.14(3)
|
Cutera,
Inc. 2004 Equity Incentive Plan, as amended by its Board of Directors on
April 25, 2008
|
|
31.1
|
Certification
of Chief Executive Officer pursuant to Section 302 of the Sarbanes-Oxley
Act of 2002.
|
|
31.2
|
Certification
of Chief Financial Officer pursuant to Section 302 of the Sarbanes-Oxley
Act of 2002.
|
|
32.1
|
Certification
of Chief Executive Officer and Chief Financial Officer pursuant to 18
U.S.C Section 1350, as adopted pursuant to Section 906 of the
Sarbanes-Oxley Act of 2002.
|
(1)
|
Incorporated
by reference from our Registration Statement on Form S-1 (Registration
No. 333-111928) which was declared effective on March 30,
2004.
|
||
(2)
|
Incorporated
by reference from our Annual Report on Form 10-K filed with the SEC on
March 25, 2005.
|
||
(3)
|
Incorporated
by reference from our Definitive Proxy Statement on Form 14A filed with
the SEC on April 28, 2008.
|
CUTERA,
INC.
|
/S/
RONALD J. SANTILLI
|
Ronald
J. Santilli
|
Executive Vice President and Chief Financial Officer
|
(Principal
Financial and Accounting Officer)
|
Date:
November 2, 2009
|
/S/
KEVIN P. CONNORS
|
|
Kevin
P. Connors
|
||
President,
Chief Executive Officer and Director
|
||
(Principal
Executive Officer)
|
Date:
November 2, 2009
|
/S/
RONALD J. SANTILLI
|
|
Ronald
J. Santilli
|
||
Executive
Vice President and Chief Financial Officer
|
||
(Principal
Financial and Accounting Officer)
|
Date:
November 2, 2009
|
/S/
KEVIN P. CONNORS
|
|
Kevin
P. Connors
|
||
President,
Chief Executive Officer and Director
|
||
(Principal
Executive Officer)
|
Date:
November 2, 2009
|
/S/
RONALD J. SANTILLI
|
|
Ronald
J. Santilli
|
||
Executive
Vice President and Chief Financial Officer
|
||
(Principal
Financial and Accounting Officer)
|